US 12,324,837 B2
ROR1-specific antigen binding molecules
Estelle Grace McLean, Craigavon (GB); Paul Richard Trumper, Craigavon (GB); Jennifer Thom, Craigavon (GB); Timothy Harrison, Craigavon (GB); Graham John Cotton, Craigavon (GB); Caroline Barelle, Craigavon (GB); Andrew Porter, Craigavon (GB); and Marina Kovaleva, Craigavon (GB)
Assigned to ALMAC DISCOVERY LIMITED, Craigavon (GB)
Appl. No. 16/957,075
Filed by Estelle Grace McLean, Craigavon (GB); Paul Richard Trumper, Craigavon (GB); Jennifer Thom, Craigavon (GB); Timothy Harrison, Craigavon (GB); Graham John Cotton, Craigavon (GB); Caroline Barelle, Craigavon (GB); Andrew Porter, Craigavon (GB); and Marina Kovaleva, Craigavon (GB)
PCT Filed Dec. 21, 2018, PCT No. PCT/EP2018/086823
§ 371(c)(1), (2) Date Jun. 22, 2020,
PCT Pub. No. WO2019/122447, PCT Pub. Date Jun. 27, 2019.
Claims priority of application No. 1721802 (GB), filed on Dec. 22, 2017.
Prior Publication US 2023/0203155 A1, Jun. 29, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/42 (2025.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); G01N 33/574 (2006.01)
CPC A61K 39/39558 (2013.01) [A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/4202 (2025.01); A61K 47/68031 (2023.08); A61K 47/68035 (2023.08); A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); A61K 47/6851 (2017.08); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 16/2863 (2013.01); C07K 16/46 (2013.01); G01N 33/57492 (2013.01); A61K 2039/5156 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/03 (2013.01); C07K 2319/30 (2013.01); C07K 2319/33 (2013.01); G01N 2333/70503 (2013.01); G01N 2333/71 (2013.01)] 57 Claims
 
1. A receptor tyrosine kinase-like orphan receptor 1 (ROR1) specific antigen binding molecule comprising an amino acid sequence represented by the formula (I):
FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4  (I)
wherein
FW1 is a framework region;
CDR1 is a CDR sequence of DTSYGLYS (SEQ ID NO: 1);
FW2 is a framework region;
HV2 is a hypervariable sequence of TTDWERMSIG (SEQ ID NO: 6);
FW3a is a framework region;
HV4 is a hypervariable sequence of NKGAK (SEQ ID NO: 11);
FW3b is a framework region;
CDR3 is a CDR sequence of REARHPWLRQWY (SEQ ID NO: 17); and
FW4 is a framework region.